Rhamnolipid-assisted black phosphorus nanosheets with efficient isolinderalactone loading against drug resistant Helicobacter pylori

• Published in: Materials & Design
• Main Authors: Yanqiang Huang, Rujia Li, Yuanyuan Dai, Chun Qin, Jikai He, Shixian Yang, Tengqi Wang, Yujie Su, Lizhou Jia, Wei Zhao
• Format: Article
• Language: English
• Published: Elsevier 2022-04-01
• Subjects: H. Pylori; Drug resistance; Black phosphorus; Isolinderalactone; Antibacterial; Photothermal therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S0264127522001575

Oral administration remains the main treatment for H. pylori infection, but the acidic environment of the stomach, the biofilm and drug resistance of H. pylori severely impair the antibacterial effect of orally clinical drugs. Here, a multifunctional nanodrug, composed of rhamnolipid-assisted black phosphorus nanocomposite (RHL@BP), is engineered for drug resistant H. pylori (H. pylori-R) treatment. The nanosystem is utilized to efficiently deliver isolinderalactone (ISL), a kind of sesquiterpenoids compound purified from traditional Chinese medicine, exhibiting significantly enhanced antibacterial ability against H. pylori-R under near-infrared (NIR) irradiation. The acid sensitivity of BP and photothermal instability of RHL could trigger the controlled and efficient release of ISL, exhibiting significant synergistic antibacterial activity against H. pylori-R in combined with NIR irradiation. In an H. pylori-R infected mice model, the amount of remnant H. pylori-R in the combination of RHL@BP/ISL and NIR irradiation without antacid group was significantly lower than that of in the conventional triple therapy group (P < 0.001). In conclusion, the multifunctional RHL@BP/ISL demonstrated a comprehensive application of acid sensitivity, biofilm eradication, antibacterial agent and photothermal to treat H. pylori-R, providing a newly potential strategy for clinical treatment of H. pylori-R infections.